OCUL
Ocular Therapeutix, Inc.
NASDAQ · USHealthcareBiotechnology
$8.71-2.90%
Price as of Jul 20, 2026
OCUL profitability
Ocular Therapeutix, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 87.2%
- EBITDA margin
- -527.0%
- EBIT margin
- -575.4%
- Net margin
- -558.2%
- Free cash flow margin
- -463.0%
Returns
- Return on equity
- -50.0%
- Return on assets
- -39.7%
- Return on invested capital
- -45.3%
- Asset turnover
- 0.07x
Cash efficiency
- Cash from operations
- -$226.2M
- Cash per share
- $3.04
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.